IMP 761

Drug Profile

IMP 761

Alternative Names: IMP761

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Prima BioMed
  • Class Monoclonal antibodies
  • Mechanism of Action CD223 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 02 Jan 2017 IMP 761 is available for licensing as of 02 Jan 2017.
  • 02 Jan 2017 Early research in Autoimmune disorders in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top